Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galanin (1-15) is a synthetic peptide comprising the first 15 amino acids of the neuropeptide galanin. Galanin (1-15) acts primarily as an agonist at the galanin receptor family, including galanin receptor 1 (GALR1), galanin receptor 2 (GALR2), and galanin receptor 3 (GALR3), which are G protein-coupled receptors distributed throughout the central and peripheral nervous systems. This peptide fragment retains significant biological activities of the full-length galanin, such as neuromodulatory, anticonvulsant, and anti-obesity effects[6][2]. Galanin and its active fragments like galanin (1-15) modulate neuronal excitability, synaptic transmission, feeding behavior, energy homeostasis, inflammatory responses, and neuroendocrine functions through their interaction with galanin receptors[6][4][2]. In experimental studies, galanin and its fragments demonstrate anticonvulsant, anti-obesity, and potential neuroprotective effects, and are being explored for therapeutic roles in epilepsy, obesity, eating disorders, mood disorders, inflammatory diseases, and neurodegenerative diseases such as Alzheimer's disease[6][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on galanin (1-15).